Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Odronextamab in Relapsed/ Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Before and After Chimeric Antigen Receptor (CAR) T-Cell Therapy

NCT06854159 is registered in ClinicalTrials.gov with University of California, Davis as lead sponsor.

NCT NCT06854159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06854159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Odronextamab in Relapsed/ Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Before and After Chimeric Antigen Receptor (CAR) T-Cell Therapy
Lead sponsor
University of California, Davis
Phase
Phase 2
Overall status
Recruiting
Start date
August 7, 2025
Completion date
January 31, 2029
Enrollment
34 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent diffuse large b-cell lymphoma, recurrent transformed follicular lymphoma to diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, refractory transformed follicular lymphoma to diffuse large b-cell lymphoma